References
- Stupp RA, Hegi ME, Mason WP et al. Efficacy of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomized Phase III study: 5-analysis of the EORTC–NCIC trial. Lancet Oncol.10(5), 459–466 (2009).
- Wong ET, Gautam S, Malchow C, Lun M, Pan E, Brem S. Bevacizumab for recurrent glioblastoma multiforme: a meta-analysis. J. Natl Compr. Canc. Netw.9(4), 403–407 (2011).
- Reardon DA, Turner S, Peters KB et al. A review of VEGF/VEGFR-targeted therapeutics for recurrent glioblastoma. J. Natl Compr. Canc. Netw.9(4), 414–427 (2011).
- De Groot JF, Lamborn KR, Chang SM et al. Phase II study of aflibercept in recurrent malignant glioma: a North American Brain Tumor Consortium Study. J Clin Oncol.29(19), 2689–2695 (2011).
- De Groot JF, Piao Y. Anti-VEGF but not VEGF receptor inhibitor therapy prolongs survival and blocks myeloid cell recruitment to orthotopic glioblastoma. Proc. Am. Assoc. Cancer Res.51, 553 (2010).
- Scott BJ, Quant EC, McNamara MB et al. Bevacizumab salvage therapy following progression in high-grade glioma patients treated with VEGF receptor tyrosine kinase inhibitors. Neuro-Oncol.12(6), 603–607 (2010).
- Norden AD, Young GS, Setayesh K et al. Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and pattern of recurrence. Neurology70(10), 779–787 (2008).
- Reardon DA, Fink KL, Mikkelsen T et al. Randomized Phase II study of cilengitide, an integrin-targeting arginine-glycine-aspartic acid peptide, in recurrent glioblastoma multiforme. J. Clin. Oncol.26(34), 5610–5617 (2008).
- Hegi ME, Diserens AC, Gorlia T et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N. Engl. J. Med.352(10), 997–1003 (2005).
- Cristofanilli M, Budd T, Ellis M et al. Circulating rumor cells, disease progression, and survival in metastatic breast cancer. N. Engl. J. Med.351(8), 781–791 (2004).
- Lun M, Lok E, Gautam S, Wu E, Wong ET. The natural history of extracranial metastasis from glioblastoma multiforme. J. Neurooncol. DOI: 10.1007/s11060-011-0575-0578 (2011) (Epub ahead of print).
- Lehtinen MK, Zappaterra MW, Chen X et al. The cerebrospinal fluid provides a proliferative niche for neural progenitor cells. Neuron69(5), 893–905 (2011).
- Locasale JW, Melman T, Song S et al. Metabolomics profiling of patient cerebrospinal fluid identifies signatures of malignant glioma. Neuro-Oncol. (2011) (In press).
- Lee SX, Wong ET, Swanson KD. Mitosis interference of cancer cells during anaphase by dielectric field from NovoTTF-100A. Neuro-Oncol. (2011) (In press).
- Kirson ED, Dbaly V, Tovarys F et al. Alternating electric fields arrest cell proliferation in animal tumor models and human brain tumors. Proc. Natl Acad. Sci. USA104(24), 10152–10157 (2007).
- Stupp R, Kanner A, Engelhard H et al. A prospective, randomized, open-label, Phase III clinical of NovoTTF-100A versus best standard of care chemotherapy in patients with recurrent glioblastoma. J. Clin. Oncol.28(18), LBA2007 (2011).
- Vander Heiden MG, Cantley LC, Thompson CB. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science324(5930), 1029–1033 (2009).
- Zuccoli G, Marcello N, Pisanello A et al. Metabolic management of glioblastoma multiforme using standard therapy together with a restricted ketogenic diet: case report. Nutr Metab.7, 33 (2010).
- Lowenstein PR. Cancer vaccines in glioma: how to balance the challenges of small trials, efficiency, and potential adverse events. J. Clin. Oncol.28(31), 4670–4673 (2010).
Website
- FDA approves new medical device for form of brain cancer www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm251669.htm